This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's disease (AD) has captured the attention of the public because of its predicted prevalence in the next two decades with aging of the Boomer generation, i.e. 18% of them, or 14 million. The economic impact of a half million cases increasing to the estimated million new cases of AD per year is staggering. These figures make discovery of mechanisms and treatments for the development of the AD imperative. We have preliminary data that suggest that AD patients show pre-attentional deficits, determined using the P50 auditory evoked potential, indicative of disturbances in brainstem-thalamus processes. The results showed decreased amplitude in ~40% of subjects, indicative of decreased levels of arousal, and decreased habituation to paired stimulation, indicative of decreased sensory gating in ~60% of subjects. To date, no studies using the Psychomotor Vigilance Task (PVT), a recognized measure of attention using simple reaction time, has been used in AD patients in combination with P50 potential pre-attentional measures. The participants will be selected from our cohort of 200 well-characterized AD patients (clinical work up, history, standard battery of neuropsychological tests and an MRI). In addition to these tests, routine for assessing participants, patients will be assessed for P50 potential and PVT performance. These studies will provide data for the submission of an NIH grant application for the implementation of preclinical studies, with a view toward developing clinical trials to determine quantitatively if AD patients include two separate populations who require specific and different treatment strategies to alleviate deficits in pre-attentional and/or attentional processing.
Aim 3. Determine if rTMS treatment promotes lasting improvement in tinnitus patients. All patients will be reassessed at 3 and 6 months post-rTMS on behavioral measures (RT) and questionnaires. In addition, the 5 best and 5 worst responders, based on perceived tinnitus at 6 months, will also have a repeat PET-CT at 6 months and a repeat of all assessments, including PET-CT, at 12 months. Novel Studies on Sites of Action and Mechanisms in Balance Dysfunction Specific Aim 1. Investigate the role of the ascending Reticular Activating System (RAS). We will measure the output of the RAS, i.e. pre-attentional/arousal processes, using the sleep state-dependent P50 midlatency auditory evoked potential, whose amplitude is a measure of level of arousal, and whose habituation to repetitive stimuli is a measure of sensory gating, the process behind distractibility.
Specific Aim 2. Investigate thalamo-cortical processing. We will assess attentional processing using the Psychomotor Vigilance Task (PVT), a measure of simple (not choice) reaction time, and evaluate the patient's ability to sustain attention and respond in a timely manner to salient signals. We will test the participant's ability to select a specified stimulus from two or more choice stimuli presented by using the Continuous Performance Task (CPT) which is a standardized clinical measure of attention, reaction time, and distractibility.
Specific Aim 3. Investigate cortical function. We will measure relative frontal lobe blood flow using Near Infrared Spectroscopy (NIRS) before and during performance of the P50 and PVT tasks to assess changes in relative blood flow to cortical regions involved in critical judgment, which are impaired in depression and other psychiatric disorders. Additionally, we will administer the Wisconsin Card Sorting Task (WCST) to access human frontal lobe function and to measure the participant's ability to shift attention from one category to another (set-shifting) with no warning using a trial and error paradigm. We will use the Operant Test Battery (OTB) to evaluate the higher cognitive functions of short-term memory, time estimation, and learning. This design will allow us to determine at which level of the neuraxis (brainstem-thalamus, thalamo-cortical, and/or cortical) patients with balance disorders manifest quantitative physiological deficits. By localizing the level of the neuraxis affected, we can develop more informed therapies that may selectively alleviate pre-attentional, attentional, and/or cognitive deficits. The proposed research will provide answers to the following questions: Do patients with balance disorders show differential changes in P50 potential amplitude, i.e. level of arousal? Do these patients show differential changes in P50 potential habituation, i.e. sensory gating? Do they show differences in mean reaction time, number of lapses, or other measures of simple attentional mechanisms? Do they show differences in higher cognitive function as evidenced by performance accuracies and latencies in short-term memory, time perception, and learning tasks? Do they show differences in relative frontal lobe blood flow before (i.e. continuous hypofrontality) and/or during (i.e. task-related) the performance of an attentional task? Quantitative physiological investigation of these potential neurological substrates for balance disorders represents a novel, comprehensive program of research with great promise for developing innovative therapies for this condition.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR020146-07
Application #
8168238
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Project Start
2010-05-01
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
7
Fiscal Year
2010
Total Cost
$216,047
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Odle, Angela; Allensworth-James, Melody; Childs, Gwen V (2018) The War on the Placenta: The Differing Battles of High-Fat Diet and Obesity. Endocrinology 159:1642-1643
MacNicol, Melanie C; Cragle, Chad E; McDaniel, F Kennedy et al. (2017) Evasion of regulatory phosphorylation by an alternatively spliced isoform of Musashi2. Sci Rep 7:11503
Rhee, Christopher J; Kaiser, Jeffrey R; Rios, Danielle R et al. (2016) Elevated Diastolic Closing Margin Is Associated with Intraventricular Hemorrhage in Premature Infants. J Pediatr 174:52-6
Odle, Angela Katherine; Allensworth-James, Melody; Haney, Anessa et al. (2016) Adipocyte Versus Somatotrope Leptin: Regulation of Metabolic Functions in the Mouse. Endocrinology 157:1443-56
Gannon, Brenda M; Williamson, Adrian; Suzuki, Masaki et al. (2016) Stereoselective Effects of Abused ""Bath Salt"" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation. J Pharmacol Exp Ther 356:615-23
Rhee, Christopher J; Kibler, Kathleen K; Easley, R Blaine et al. (2016) The Diastolic Closing Margin Is Associated with Intraventricular Hemorrhage in Premature Infants. Acta Neurochir Suppl 122:147-50
Odle, Angela K; Allensworth-James, Melody L; Akhter, Noor et al. (2016) A Sex-Dependent, Tropic Role for Leptin in the Somatotrope as a Regulator of POU1F1 and POU1F1-Dependent Hormones. Endocrinology 157:3958-3971
MacNicol, Melanie C; Cragle, Chad E; Arumugam, Karthik et al. (2015) Functional Integration of mRNA Translational Control Programs. Biomolecules 5:1580-99
Rhee, Christopher J; Fraser 3rd, Charles D; Kibler, Kathleen et al. (2015) Ontogeny of cerebrovascular critical closing pressure. Pediatr Res 78:71-5
Odle, Angela K; Drew, Paul D; Childs, Gwen V (2015) Giant mice reveal new roles for GH in regulating the adipose immune microenvironment. Endocrinology 156:1613-5

Showing the most recent 10 out of 156 publications